PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022

Share Article

Reportbuyer.com just published a new market research report: PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022.

PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022”. Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.

The DES market in China is projected to grow substantially during the forecast period. During the forecast period, the primary growth driver in this market will be the launch of Diquas and CF101 and generally increased access to medical care for China’s enormous population.

Scope

-Overview of the DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for the top drugs in China from 2012-2022.
-Analysis of the impact of key events as well the drivers and restraints affecting China DES market.

Reasons to buy

-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for DES
-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-Make more informed business decisions from insightful and in-depth analysis of drug performance
-Obtain sales forecast for drugs from 2012-2022 in China.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 12
3.1.3 Classification 14
3.1.4 Prognosis 14
3.1.5 Quality of Life 15
3.2 Symptoms 15
4 Disease Management 17
4.1 Overview 17
4.1.1 Diagnosis Overview 17
4.1.2 Treatment Guidelines 19
4.1.3 Treatment Overview 24
4.2 China 27
4.2.1 Diagnosis 27
4.2.2 Clinical Practice 27
5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 28
5.3 Product Profiles – Major Brands 30
5.3.1 Diquas (diquafosol tetrasodium) 30
5.3.2 Additional Therapies 33
6 Opportunity and Unmet Need 37
6.1 Overview 37
6.2 Diagnostic tests are not specific enough to identify subgroups of patients 38
6.3 Frequent dosing and side effects limit compliance 39
6.4 Lack of physician and patient awareness 40
6.5 Trial design may be a factor in so few drugs being approved 41
6.6 Unmet Needs Gap Analysis 42
6.7 Comprehensive method for measuring dry eye signs and severity levels 43
6.8 Increase treatment rates among milder forms of the disease 44
7 Pipeline Assessment 45
7.1 Overview 45
7.2 Promising drugs in clinical development 46
7.2.1 CF-101 47
8 Market Outlook 51
8.1 China 51
8.1.1 Forecast 51
8.1.2 Key Events 53
8.1.3 Drivers and Barriers 53
9 Appendix 55
9.1 Bibliography 55
9.2 Abbreviations 58
9.3 Methodology 60
9.4 Forecasting Methodology 60
9.4.1 Diagnosed DES patients 60
9.4.2 Percent Drug-treated Patients 61
9.4.3 Drugs Included in Each Therapeutic Class 61
9.4.4 General Pricing Assumptions 61
9.4.5 Individual Drug Assumptions 62
9.4.6 Generic Erosion 63
9.5 Physicians and Specialists Included in this Study 64
9.6 About the Authors 65
9.6.1 Author 65
9.6.2 Global Head of Healthcare 66
9.7 About GlobalData 67
9.8 Contact Us 67
9.9 Disclaimer 67
1.1 List of Tables

Table 1: Symptoms of Dry Eye Syndrome 16
Table 2: Treatment Guidelines for Dry Eye Syndrome 24
Table 3: Commonly Prescribed Drugs for Dry Eye Syndrome by Class in the Global Markets, 2012 26
Table 4: Leading Treatments for Dry Eye Syndrome, 2012 29
Table 5: Product Profile – Diquas 31
Table 6: Diquas SWOT Analysis, 2012 33
Table 7: Summary of Minor Drug Classes, 2012 36
Table 8: Overall Unmet Needs – Current Level of Attainment 38
Table 9: Clinical Unmet Needs – Gap Analysis, 2012 43
Table 10: Dry Eye Syndrome – Phase Pipeline, 2012 46
Table 11: Comparison of Therapeutic Classes in Development for Dry Eye Syndrome, 2012 47
Table 12: Product Profile – CF101 48
Table 13: CF101 SWOT Analysis, 2012 50
Table 14: Sales Forecasts ($m) for Dry Eye Syndrome in China, 2012–2022 52
Table 15: Key Events Impacting Sales for Dry Eye Syndrome China, 2012–2022 53
Table 16: China, Dry Eye Syndrome Market – Drivers and Barriers, 2012–2022 53
1.2 List of Figures

Figure 1: Dry Eye Syndrome – Disease Etiology 11
Figure 2: Tear Film in Normal Eye and Dry Eye 12
Figure 3: Sequence of Diagnostic Tests Used to Diagnose Dry Eye Syndrome 17
Figure 4: Delphi Panel Treatment Recommendations for Dysfunctional Tear Syndrome Without Lid Margin Disease, 2006 20
Figure 5: Delphi Panel Treatment Recommendations for Dysfunctional Tear Syndrome With Lid Margin Disease and Abnormal Tear Distribution, 2006 21
Figure 6: Treatment Recommendations for Dry Eye Syndrome from the Management and Therapy Subcommittee, Dry Eye Workshop, 2007 22
Figure 7: American Academy of Ophthalmology Preferred Practice Pattern for Dry Eye, 2011 23
Figure 8: Competitive Assessment of Late-Stage Pipeline Agents in Dry Eye Syndrome, 2012–2022 46
Figure 9: Sales for Dry Eye Syndrome in China by Drug Class, 2012–2022 52

Read the full report:

PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022

http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_dry_eye_syndrome_china_drug_forecast_market_analysis_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sarah Smith
Research Advisor at Reportbuyer.com
+44 208 816 85 48
Email >
Visit website